You are here: Home » Companies » News
Business Standard

Bharat Biotech's typhoid vaccine rated high in latest human trials

Vaccine is safe, 100% immunogenic, and prevents 55% of typhoid infections in the challenge trial and up to 87% infections

BS Reporter  |  Hyderabad 

Animal vaccine

Hyderabad-based maker on Monday announced that its next-generation vaccine, has demonstrated its safety and efficacy in a high-risk human challenge clinical study carried out at Oxford University. The clinical studies conducted on human subjects produced 87 per cent effectiveness according to the trial results published in Lancet, the company said.

The study is the first to demonstrate that immunisation with is safe, well tolerated and will have a significant impact on disease incidence in endemic areas that introduce the The study was conducted in 112 adult volunteers and used a controlled human model.

According to the study published in Lancet, the is safe, 100 per cent immunogenic, and prevents 55 per cent of infections in the challenge trial and up to 87 per cent infections, when using real-life definitions of fever.

The data is highly significant since the currently available vi-ps vaccines cannot be administered to children below 2 years of age, and do not confer long-term immunity. can be administered to children below 2 years and does confer long-term immunity, according to

"The company is pleased that the has been found to be extremely effective in the first ever high-risk human challenge studies. The results of this study and the 87 percent effectiveness success endorse more than 10 years of R&D efforts to develop this and various clinical trials that have been carried out over the past 8 years," chairman and managing director Krishna Ella said.

The product summary file has been submitted to (WHO) for prequalification. prequalification would allow for UNICEF to procure this for low-income countries where the disease burden is very high. Typbar TCV is currently licensed in India, Nigeria and Nepal, with registrations underway in Malaysia, Turkey etc among 30 other countries, the company said.

has been supporting Acceleration Consortium. is working with the Consortium in carrying out field trials in different countries to evaluate the efficacy of Typbar TCV.

First Published: Mon, October 02 2017. 16:40 IST
RECOMMENDED FOR YOU